image credit: Pxhere

Abiomed enrols first subject in Impella heart pump trial

April 16, 2021


Abiomed has enrolled the first patient in the PROTECT IV trial, which aims to obtain the clinical evidence needed to get a Class I guideline recommendation for Impella heart pumps in high-risk percutaneous coronary intervention (HRPCI).

The first patient was enrolled at Ascension St John Hospital in Detroit, US.

Ascension St John Macomb-Oakland Hospital cardiology chief Dr Ted Schreiber said: “This trial aims to generate the highest level of scientific clinical evidence to definitively demonstrate that Impella-supported PCI improves outcomes for high-risk patients, and we are excited to enrol the first patient in the trial.”